[ANAC] Anacor Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 4.5 B

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 99.2 Change: 0 (0%)
Ext. hours: 99.06 Change: 0 (0%)

chart ANAC

Refresh chart

Description: Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company?s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis, and chronic inflammatory skin diseases. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company?s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed Phase IIa clinical trials for the treatment of

Fundamental Ratios
Shares Outstanding45.38 M EPS-1.46 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 420.78% Sales Growth - Q/Q58.31% P/E-67.95
P/E To EPS Growth P/S141.6 P/BV62 Price/Cash Per Share25.66
Price/Free Cash Flow-112.49 ROA-36.73% ROE-101.8% ROI
Current Ratio4.58 Quick Ratio Long Term Debt/Equity0.42 Debt Ratio0.52
Gross Margin Operating Margin-259.46% Net Profit Margin-248.29% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.58 M Cash From Investing Activities-2.19 M Cash From Operating Activities5.68 M Gross Profit14.51 M
Net Profit-12.96 M Operating Profit-11.8 M Total Assets214.89 M Total Current Assets186.28 M
Total Current Liabilities40.69 M Total Debt60.81 M Total Liabilities142.3 M Total Revenue15.26 M
Technical Data
High 52 week114.27 Low 52 week56.83 Last close99.2 Last change0%
RSI50.62 Average true range14.3 Beta0.18 Volume
Simple moving average 20 days-0% Simple moving average 50 days15.77% Simple moving average 200 days
Performance Data
Performance Week0% Performance Month-0.23% Performance Quart64.76% Performance Half32.23%
Performance Year11.45% Performance Year-to-date0% Volatility daily0.08% Volatility weekly0.18%
Volatility monthly0.37% Volatility yearly1.26% Relative Volume0% Average Volume2.5 M
New High New Low


2017-08-01 09:09:56 | Dupixent Could Substantially Drive Regeneron’s Growth

2017-03-23 09:06:03 | New Product Launches May Boost Valeant’s Dermatology Revenue

2016-12-29 07:35:48 | Why Did Valeant Pharmaceuticals Update Its 2016 EPS Guidance?

2016-11-17 18:04:11 | AnacorAcquisition Added Crisaborole to Pfizer’s Portfolio

2016-10-14 08:04:53 | Four Key Deals: Analyzing Pfizer’s Impending Growth

2016-09-29 18:04:12 | The Pfizer-Anacor Deal: A Review

2016-09-26 09:02:21 | Drugmaker Pfizer decides not to break up business

2016-08-29 08:05:46 | What Investors Should Know about the Pfizer-Anacor Deal

2016-08-18 09:06:00 | Why Pfizer's Acquisition of Anacor Is a Great Fit

2016-08-18 09:06:00 | Why Pfizer's Acquisition of Anacor Is a Great Fit

2016-08-12 09:04:39 | Pfizer-Anacor Deal Completed in June 2016

2016-08-02 13:02:35 | Pfizer beats Street 2Q forecasts despite big drop in profit

2016-07-22 08:06:00 | Will Pfizer Book Another Healthy Quarter?

2016-07-06 20:06:15 | What Can We Expect from the Pfizer-Anacor Deal?

2016-07-06 20:06:11 | The Pfizer-Anacor Deal Wrapped Up in June: Now What?

2016-06-24 13:21:10 | Pfizer Completes Anacor Acquisition

2016-06-24 13:10:04 | Pfizer Completes Acquisition Of Anacor

2016-06-24 09:22:00 | ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Event

2016-06-23 20:37:12 | Why Pfizer PFE is a Great Stock to Buy for the Long Run

2016-06-15 17:26:00 | Will A New Suitor For Anacor Emerge?

2016-06-08 16:30:23 | ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub

2016-06-05 10:03:00 | Why Anacor Pharmaceuticals, Inc. Stock Jumped 58.3% in May

2016-05-30 13:02:00 | Better Buy: Novavax, Inc. vs. Pfizer Inc.

2016-05-30 03:47:55 | How Wellcome and Gates charities profit from helping biotech

2016-05-30 03:25:28 | How Wellcome and Gates charities profit from helping biotech

2016-05-26 17:29:00 | Anacor received rival bid before Pfizer deal - filing

2016-05-26 15:36:48 | Anacor reveals receiving rival bid before Pfizer deal - filing

2016-05-25 18:19:00 | Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits

2016-05-25 17:37:00 | Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio

2016-05-25 09:07:29 | XBI’s and IHI’s Mid-Caps Soared, Overturning 2 Weeks of Losses

2016-05-24 12:24:00 | Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why

2016-05-17 01:14:51 | Analysis - Pfizer's Anacor deal showcases new wave of eczema therapies

2016-05-16 18:21:07 | Pfizer buys skin drug maker Anacor

2016-05-16 14:22:05 | Pfizer to Acquire Anacor

2016-05-16 13:46:19 | Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel

2016-05-16 13:35:34 | Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel

2016-05-16 07:32:10 | Pfizer to Acquire Anacor

2016-05-15 23:53:22 | Pfizer to buy eczema specialist for $5.2 billion

2016-05-10 07:18:11 | Anacor Pharmaceuticals Reports First Quarter 2016 Financial Results

2016-05-09 04:26:08 | Anacor Pharmaceuticals to Report First Quarter 2016 Financial Results on May 10, 2016

2016-05-04 16:20:12 | Anacor Pharmaceuticals to Report First Quarter 2016 Financial Results on May 10, 2016

2016-05-02 08:50:05 | Anacor Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference

2016-03-31 20:53:22 | Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023

2016-03-30 16:21:09 | Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023

2016-03-22 08:49:22 | Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis